Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement

San Diego, (PresseBox) - Cytori Therapeutics (NASDAQ: CYTX) has entered into a Celution® System agreement with Apollo Hospitals, one of Asia's largest private healthcare groups, to offer the technology initially at select cosmetic surgery centers in India.

"At Apollo Hospitals, we pride ourselves on introducing the latest technological medical advancements," said Dr. Prathap C. Reddy, founder and Chairman of Apollo Hospitals Group. "The alliance with Cytori has the potential to revolutionize the delivery of personalized cell therapy in India. The Cytori Celution® System represents best-in-class regenerative medicine technology that enables surgeons' access to the power of the patient's own regenerative cells as real-time therapy for cosmetic surgery as well as a variety of other ischemic conditions."

Apollo Hospitals is a core customer around which Cytori can build a successful commercial business in India. This agreement follows a clinical evaluation of Celution®-based soft tissue procedures performed by Apollo. More information about Apollo Hospitals Group can be found at http://www.apollohospitals.com/.

Cytori Therapeutics, Inc.

Cytori is a leader in cell therapy, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications. Our PureGraft(TM) products are available in North America and Europe for fat grafting procedures. www.cytori.com

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.